NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
Celldex Therapeutics
MiMedx Group, Inc.
ProTiP Medical
Atos Medical AB
Pharmacyclics LLC.